ArticleFrontiers in immunology2026
Treatment for intermediate and advanced-stage hepatocellular carcinoma: does systemic therapy synergize the therapeutic efficacy of TACE?
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Pre-TACE CK-MB/CK Ratio as an Independent Prognostic Biomarker in Advanced Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage hepatocellular carcinoma (HCC), but its efficacy varies due to patient heterogeneity. Combining TACE with systemic therapies, such as targeted agents or immune checkpoint inhibitors, has shown promise in improving outcomes, though controversies regarding survival benefits and safety persist. This study investigates whether synchronized systemic therapy enhances the therapeutic efficacy of TACE in intermediate and advanced-stage HCC. Methods: This single-center, retrospective study included 142 patients with intermediate and advanced-stage HCC (BCLC B or C) who received TACE as initial treatment between February 2019 and August 2022 at Hunan Provincial People's Hospital. Patients were divided into two groups: combination therapy (TACE plus systemic therapy, n=41) and TACE monotherapy (n=101). Progression-free survival (PFS), overall survival (OS), treatment response (per mRECIST criteria), and adverse events (AEs) were compared. Cox regression and Kaplan-Meier analyses were used to assess survival outcomes. Results: No significant differences were observed in baseline characteristics, except for a higher proportion of Child-Pugh A patients in the combination group (90.2% vs. 67.3%, P= 0.005). Median PFS was similar between the combination and monotherapy groups (5.5 vs. 6.0 months, P= 0.832), with no significant differences in BCLC-B (18.3 vs. 17.4 months, P= 0.516) or BCLC-C (4.1 vs. 3.7 months, P= 0.255) subgroups. However, the combination group showed a trend toward improved OS (24.8 vs. 16.7 months, P= 0.282), with a significant benefit in BCLC-C patients (17.9 vs. 11.0 months, P= 0.048). Grade 3 or 4 AEs were comparable between groups (7.2% vs. 14.9%, P= 0.187). Conclusion: Combining systemic therapy with TACE does not improve PFS but may enhance OS in BCLC-C patients. The safety profile is comparable, particularly in patients with preserved liver function. These findings highlight the importance of patient selection and warrant further prospective studies to optimize treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.